Immuno-Biological Laboratories (4570) · RiskDropped
Uncertainty Regarding Joint Research with Public Research Institutions and Universities and the Acquisition of Rights
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: FY2020.
3entries
4years
0from disclosures
How it moved
Same theme, other companies
Risk of dependence on joint R&D counterparties and termination of agreementsA theme 16 companies write about · 19 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2020: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.Full recordFilings, disclosures and news, newest first
- FY2020DroppedAnnual reportNo standalone risk disclosure concerning the uncertainty surrounding joint research with public research institutions and universities and the acquisition of rights can be confirmed in this filing.
- FY2019RestatedAnnual report
「Accordingly, the Group may be unable to conduct joint research or acquire rights as anticipated, and this could have a significant impact on its business strategy and financial results.」
The filing reiterates the uncertainty that joint research with public research institutions and universities and the acquisition of rights may be affected by laws, regulations and internal rules. - FY2017First statedAnnual report
「Accordingly, the Group may be unable to conduct joint research or acquire rights as anticipated, and this could have a significant impact on its business strategy and financial results.」
For the first time, the filing independently identifies the risk that collaboration with public research institutions and universities may be affected by laws, regulations and internal rules, preventing joint research and the acquisition of intellectual property rights from proceeding as anticipated.